权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Comprehensive analyses of endogenous retroviruses with severe chronic fatigue syndrome

内源性逆转录病毒与严重慢性疲劳综合征的综合分析

基本信息

批准号：
10342264
负责人：
Dawei Li
金额：
$ 7.38万
依托单位：
FLORIDA ATLANTIC UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-02-05 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10342264
关键词：
Comprehensive analyses endogenous retroviruses severe

项目摘要

Project Summary/Abstract Myalgic encephalomyelitis/chronic fatigue syndrome (referred to as CFS) is a debilitating disease characterized by unrelenting fatigue, post-exertional malaise, cognitive impairment, sleep problems, and pain. CFS disables 1-2.5 million Americans, and costs $17–24 billion annually. Clinical tests of CFS patients are typically normal. There are currently no molecular biomarkers or FDA-approved treatments. The cause of CFS is unknown. Recent data from ourselves and others show that CFS is a complex and misunderstood disease. This proposal is aimed at helping to understand the role of endogenous retrovirus (ERV) variations in the genetic predisposition for CFS. We propose a novel CFS model: polymorphic ERV insertions can be activated through demethylation, infectious agents, or both, and the resembled viral RNA triggers the inflammation pathway, ultimately leading to CFS. The co-contribution of genome-wide ERV variations and their activators is an unexplored research frontier and an important area for research in CFS. Here, we will focus on analyzing existing CFS genome, methylome, transcriptome, and microbiome data to identify ERV variations associated with CFS. Verifying ERV as a risk factor in CFS will aid in adoption of an antiviral or anti-inflammatory treatment or anti-inflammatory lifestyle. If ERV activators, such as demethylation or infectious agent triggers, are also found, research on this will eventually lead to new therapeutic intervention and prevention.

项目摘要/摘要肌痛性脑脊髓炎/慢性疲劳综合征(简称CFS)是一种使人衰弱的疾病。以无休止的疲劳、劳累后的不适、认知障碍、睡眠问题和疼痛为特征。 CFS导致100-250万美国人残疾，每年花费170-240亿美元。CFS患者的临床测试是通常是正常的。目前还没有分子生物标记物或FDA批准的治疗方法。慢性疲劳综合征的病因是未知的。来自我们和其他人的最新数据表明，CFS是一种复杂的、被误解的疾病。这一建议旨在帮助了解内源性逆转录病毒(ERV)变异在人类免疫缺陷病毒感染中的作用慢性疲劳综合征的遗传易感性。我们提出了一种新的CFS模型：可以激活多态ERV插入通过去甲基化，感染性因素，或两者兼而有之，以及类似的病毒RNA触发炎症途径，最终导致慢性疲劳综合征。全基因组ERV变异及其激活子的共同贡献是这是一个尚未探索的研究前沿，也是CFS研究的重要领域。在这里，我们将重点分析现有的CFS基因组、甲基组、转录组和微生物组数据，以识别相关的ERV变异使用CFS。证实ERV是CFS的危险因素将有助于采用抗病毒或抗炎药物治疗或消炎的生活方式。如果ERV激活剂，如去甲基化或感染剂触发，对此的研究最终将导致新的治疗干预和预防。